大又大又粗又硬又爽少妇毛片,国产亚洲熟妇在线视频,日日碰狠狠躁久久躁综合网,欧美成人无码A片免费一区澳门

Visterra  
Visterra發(fā)現(xiàn)和開發(fā)新型抗體應對重大傳染病的預防和治療。

Visterra discovers and develops novel antibodies for the prevention and treatment of major infectious diseases. The company’s proprietary antibody engineering technology generates unique structural information that identifies novel target epitopes (sites recognized by antibodies) and guides the design of antibodies which specifically target these epitopes to effectively combat disease. The company’s lead antibody product candidate, VIS410, is a broad spectrum monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The company is building a proprietary pipeline of novel antibodies in infectious disease, and continuing to expand its disease area focus through strategic partnerships. Visterra was founded based on scientific work developed in the laboratory of Dr. Ram Sasisekharan and licensed from MIT. The company is currently backed by Polaris Partners, Flagship Ventures, Lux Capital, the Bill & Melinda Gates Foundation, and Omega Funds.